Research Analysts Set Expectations for SABS FY2025 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for SAB Biotherapeutics in a research report issued to clients and investors on Sunday, November 23rd. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of $0.07 per share for the year, up from their prior estimate of ($0.64). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Leerink Partnrs also issued estimates for SAB Biotherapeutics’ Q4 2025 earnings at ($0.16) EPS and FY2026 earnings at ($0.37) EPS.

A number of other equities research analysts also recently issued reports on the company. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Leerink Partners assumed coverage on SAB Biotherapeutics in a report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SAB Biotherapeutics in a report on Monday, November 17th. Finally, Chardan Capital restated a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

SAB Biotherapeutics Stock Up 2.8%

Shares of SABS opened at $4.04 on Wednesday. The company has a current ratio of 10.49, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $6.60. The firm’s 50 day moving average is $2.86 and its 200-day moving average is $2.35. The stock has a market capitalization of $192.34 million, a PE ratio of -1.31 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.38.

Institutional Trading of SAB Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SABS. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics during the third quarter worth $32,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics in the third quarter worth $40,000. HB Wealth Management LLC increased its holdings in SAB Biotherapeutics by 10.9% in the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after purchasing an additional 25,800 shares during the period. Finally, Woodline Partners LP bought a new position in SAB Biotherapeutics during the 3rd quarter worth $5,730,000. 7.82% of the stock is currently owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.